
Methodist
THE METHODIST HOSPITAL

Pathology Service 6565 Fannin, M.S. 205 Houston, Texas 77030 (713) 790-2370 FAX: (713) 793-1473



May 11, 1995

Dr. Phillip Migliore
Department of Pathology
Baylor College of Medicine
One Baylor Plaza
Houston, Texas 77030

RE: Project "Expression of the Facilitative Glucose Transporter Proteins in Normal Human Digestive Tissue and their Neoplasias"

FINAL REPORT

Dear Doctor Migliore:

As expressed in the closing report dated June 8, 1993 (copy enclosed), lack of satisfactory results with the original semi-comercial antibodies required that several new antibodies be generated against extra and intracellular domains of GT1 and GT3. Whereas these new antibodies proved specific on Western blot analysis, they turned out to be inadequate for tissue studies. As a consequence, the entire funds provided by the Moran Foundation for this project were utilized without being able to generate publishable results.

I am very happy to report, however, that the line of research initiated with Moran Foundation funds has continued on with new, unrelated funds and is now proving quite fruitful. Indeed, new antibodies have been generated which have been successfully utilized in the immunostaining of tissues (abstracts listed separately). Recognizing the key role played by the original award from the Moran Foundation in the development of this currently productive line of research, credit will be happily and gratefully given in the two manuscripts generated, now in progress.

Sincerely,

Juan Lechago, M.D., Ph.D. Professor of Pathology

Director, Surgical Pathology

THE METHODIST HOSPITAL

Pathology Service 6565 Fannin, M.S. 205 Houston, Texas 77030 BAYLOR COLLEGE OF MEDICINE

Department of Pathology One Baylor Plaza Houston, Texas 77030 (713) 798-4661

June 8, 1993

Dr. Phillip Migliore Department of Pathology Baylor College of Medicine One Baylor Plaza Houston, Texas 77030

Dear Phil:

This is an updated report regarding the Moran Foundation project entitled "Expression of the Facilitative Glucose Transporter Proteins in Normal Human Digestive Tissue and their Neoplasias" with Dr. Mamoun Younes listed as co-investigator and myself as principal investigator. Lack of satisfactory results with some of the original antibodies and heavy service and administration duties by both investigators have determined that this research has progressed at a somewhat slower pace than anticipated. Nevertheless, one additional antibody directed against the extracellular domain of the glucose-binding site of GT3 has been generated and tested by ELISA. In addition, two new peptides, representing intracellular domains of GT1 and GT3, have been syntesized and antibodies are being generated against them. In recent preliminary experiments, using Western blot analysis, antibodies against extracellular domains of GT1 and GT3 have reacted with colon and pancreatic neoplastic cell lines. These cell lines are being cultured and will be utilized for further research.

On July 1, 1992, Dr. Mamoun Younes, co-investigator in the original application, joined the Faculty of the Department of Pathology and took over the main operation of this project. Whereas the original funds from the Moran Foundation have been entirely utilized, the addition of new funding from departmental sources has enabled us to continue this interesting line of research and work is expected to proceed at a swifter pace in the upcoming academic year. Of course, as publishable results are generated, credit will be happily and gratefully given to the Moran Foundation for its award.

Sincerely,

Juan Lechago, M.D., Ph.D. Professor of Pathology

Director, Surgical Pathology

ABSTRACTS

- 1. Younes M, Lechago LV, Lechago J: Glucose transporter GLUT1 is frequently expressed in colon cancer. Modern Pathol, 8:71A,1995
- 2. Younes M, Lechago L, Lechago J: Most non-small cell lung cancers (LCA) express the human erythrocyte glucose transporter (Glut1). Proceedings of the A.A.C.R. Annual Meeting, Toronto, Canada, March 18-20, 1995.